Selectis Health hit by $27M sale termination, heavy debt and going-concern doubts

Selectis Health, Inc. (OTCMKTS: GBCS) - Quick take
Selectis runs 12 long‑term care facilities in the South/Southeast. Recent operating trends show higher healthcare revenue but persistent losses, heavy debt, covenant breaches and a material liquidity shortfall. Management cites substantial doubt about going concern and planned remedies (raise occupancy/Medicaid rates, cut costs, seek financing). The previously announced $27.0M sale of four Georgia facilities was terminated by the purchaser on July 13, 2025 - removing a major expected liquidity source.

Key facts & statistics (as reported, June 30, 2025)
- Total assets: $33,637,759
- Total liabilities: $40,034,511
- Selectis stockholders' deficit: $(6,396,752)
- Cash and cash equivalents: $559,983; Restricted cash: $771,940; Total cash + restricted: $1,331,923
- Accounts receivable, net: $3,042,377
- Total debt (principal outstanding): $31,949,635; Total debt, net of discount: $31,506,067
- Current maturities of long‑term debt (net): $11,326,024; Short‑term related party debt: $775,000; Lines of credit: $708,294
- Not in compliance with two loan covenants as of June 30, 2025 (amounts included in current maturities)
- Working capital deficiency: approximately $17.2 million (management disclosure)
- Facilities owned: 12 (9 operating, 1 leased operation) - 893 total beds (operating 752 beds shown)
- Common shares outstanding: 3,067,059 (Aug 14, 2025)
- Warrants outstanding: 177,500 at $2.25 (weighted avg remaining term ~0.5 years)

Income statement - what's good
- Healthcare revenue increased: Q2 (three months ended June 30, 2025) healthcare revenue $10,441,244 vs $9,423,776 in Q2 2024 (up $1,017,468 / +11%). Six months: $20,928,183 vs $18,755,856 (+12%). Management attributes improvement to higher Medicaid rates in Georgia and Oklahoma.
- Operating cash flows improved materially: cash provided by operations for six months ended June 30, 2025 was $958,032 (vs cash used $173,423 in prior year period). Non‑cash charges (depreciation) and working capital timing contributed.
- Interest expense declined: Q2 interest expense, net $225,991 vs $585,709 in Q2 2024 (a 61% decline) - driven by payoff of the Archway mortgage after its June 2024 sale.
- One‑time Employee Retention Credit collected: $326,500 in Q2 2025 improved other income.

Income statement - negatives and risks
- Continuing losses: Q2 net loss attributable to common stockholders $(315,527) (net loss $(308,027) overall). Six months net loss $(986,496) attributable to common stockholders; consolidated six‑month net loss $(963,996).
- Loss from operations persists: Q2 loss from operations $(450,289); six months $(872,035). Operating expenses remain high (property taxes, insurance and other operating expense $8,156,177 in Q2; $16,237,146 six months).
- Decline in non‑rental revenue sources: rental revenue dropped to $0 in Q2 and for six months (compared to $161,026 and $321,352 in 2024) after sale of Archway - removing recurring rental inflows.
- Provision for credit losses trending higher: Q2 provision $136,348 (up 37% vs Q2 2024), six months $235,956 (up 18% vs prior year).
- EPS negative: basic and diluted EPS Q2 $(0.10); six months $(0.32).
- Heavy current maturities and covenant breaches increase refinancing/refund risk: $11.3M current maturities and two broken covenants raise refinancing risk and potential acceleration.
- Going concern: management explicitly discloses substantial doubt about continuation as a going concern within 12 months unless financing or asset sales occur.
- Termination of the $27.0M PSA (July 13, 2025): removes a crystalized path to liquidity; the company had already recorded a $400,000 non‑refundable deposit in other current liabilities related to that sale, but the termination materially reduces near‑term options to reduce debt.

Operational & governance issues
- Material weaknesses in disclosure controls / internal control over financial reporting: inadequate IT controls, lack of segregation of duties, and lack of multi‑level review - management plans remediation but risks remain short term.
- Legal exposure: routine healthcare liability and wrongful death suits disclosed (insurance in place, but exposure can be material).
- Concentrated operational risk: revenue dependent on Medicaid/third‑party payers and occupancy; reimbursements and regulatory changes can materially affect results.

Bottom line - concise verdict
Selectis Health is showing improving operating revenue trends (higher Medicaid rates and increased healthcare revenue) and better operating cash flow versus prior year, but those positives are outweighed by ongoing losses, heavy leverage, covenant breaches, a ~$17.2M working capital gap, material weaknesses in controls, and the loss of a planned $27M asset sale that management had been relying on. The company needs immediate financing or successful asset dispositions and remediation of control failures to remove the substantial doubt about its ability to continue as a going concern.

If you want, I can draft a short investor Q&A, a one‑page risk summary, or highlight the most material near‑term dates and cash needs to monitor.